The latest price target for ORIC Pharmaceuticals (NASDAQ:ORIC) was reported by HC Wainwright & Co. on February 21, 2025. The analyst firm set a price target for $21.00 expecting ORIC to rise to within 12 months (a possible 173.44% upside). 30 analyst firms have reported ratings in the last year.

The latest analyst rating for ORIC Pharmaceuticals (NASDAQ:ORIC) was provided by HC Wainwright & Co., and ORIC Pharmaceuticals reiterated their buy rating.

The last upgrade for ORIC Pharmaceuticals Inc happened on March 23, 2023 when HC Wainwright & Co. raised their price target to $16. HC Wainwright & Co. previously had a neutral for ORIC Pharmaceuticals Inc.

The last downgrade for ORIC Pharmaceuticals Inc happened on March 21, 2023 when Guggenheim changed their price target from N/A to $15 for ORIC Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ORIC Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ORIC Pharmaceuticals was filed on February 21, 2025 so you should expect the next rating to be made available sometime around February 21, 2026.

While ratings are subjective and will change, the latest ORIC Pharmaceuticals (ORIC) rating was a reiterated with a price target of $21.00 to $21.00. The current price ORIC Pharmaceuticals (ORIC) is trading at is $7.68, which is out of the analyst’s predicted range.